Abstract 4997
Background
Hospice care aims to optimize the quality of life of patients and their families in the last phase of life by diminishing physical, psychological, social and spiritual suffering. Expectations are associated with patient satisfaction. A theoretical framework was used, distinguishing expectations with respect to process, structure and outcomes. The aim of the study is to explore expectations of hospice care of future hospice patients.
Methods
A generic qualitative study was performed from January to July 2018. Eleven patients with a life expectancy <1 year (‘surprise question’) were enrolled. In addition, two patient advocates were included to gain a broader view on expectations. Semi structured interviews were transcribed verbatim, analyzed by 2 researchers independently and results were discussed in the research team.
Results
The participants covered a range in gender, age, spiritual beliefs, living area, primary diagnosis, phase of palliation and knowledge on the topic. Participants expect to be admitted to hospice when death was imminent and dying at home becomes impossible. They expect a homelike environment and the ability to continue living like being at home. Participants are sure that caregivers in hospice care are loving and trustworthy. Without doubt patients expect them to provide appropriate care and treatment with the skills and knowledge necessary.
Conclusions
Hospices have the responsibility to ensure nuanced and balanced information on hospice care in the Dutch society to set realistic expectations. Information about the possibilities and aims of hospice care, including short stay admissions, respite care and support at home in collaboration with primary caregivers should be widespread to ensure timely and appropriate hospice care for all patients in need.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
ZonMw.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1707 - Clinical utility of precision immunoprofiling and monitoring of the tumor microenvironment using flow cytometry and CyTOF in patients with advanced NSCLC treated with atezolizumab: results from a phase II study for biomarker analysis (EPOC1702)
Presenter: Keisuke Kirita
Session: Poster Display session 3
Resources:
Abstract
3594 - Tumor mutation burden (TMB), PD-L1, IFN-γ signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
744 - The decrease of TMB, TNB and HLA expression are the Mechanism of Drug Resistance of NSCLC to immunosuppressive PD-1/PD-l1.
Presenter: Sheng Yu
Session: Poster Display session 3
Resources:
Abstract
2350 - Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)
Presenter: Rika Kizawa
Session: Poster Display session 3
Resources:
Abstract
5930 - A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumors.
Presenter: Javier Pérez-peña
Session: Poster Display session 3
Resources:
Abstract
6127 - Alterations of TMB and TCR repertoires during Chemotherapy in East Asian lung cancer patients without TKI-related driver gene mutations
Presenter: Lele Song
Session: Poster Display session 3
Resources:
Abstract
1310 - Association of SCFA in gut microbiome and clinical response in solid cancer patients treated with andi-PD-1 antibody.
Presenter: Motoo Nomura
Session: Poster Display session 3
Resources:
Abstract
2286 - Extracellular matrix and tissue derived metabolites in a liquid biopsy identifies endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment
Presenter: Nicholas Willumsen
Session: Poster Display session 3
Resources:
Abstract
4107 - Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy
Presenter: Julie Stein
Session: Poster Display session 3
Resources:
Abstract
1291 - PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy
Presenter: Yun Fan
Session: Poster Display session 3
Resources:
Abstract